Compare CORT & INGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | INGR |
|---|---|---|
| Founded | 1998 | 1906 |
| Country | United States | United States |
| Employees | 730 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 6.4B |
| IPO Year | 2001 | 1997 |
| Metric | CORT | INGR |
|---|---|---|
| Price | $89.23 | $97.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $96.50 | ★ $128.57 |
| AVG Volume (30 Days) | 957.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.94% |
| EPS Growth | N/A | ★ 15.14 |
| EPS | N/A | ★ 2.22 |
| Revenue | $761,407,000.00 | ★ $7,219,000,000.00 |
| Revenue This Year | $26.08 | $3.86 |
| Revenue Next Year | $26.98 | $2.95 |
| P/E Ratio | ★ N/A | $43.98 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $94.44 |
| 52 Week High | $91.00 | $137.57 |
| Indicator | CORT | INGR |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | 42.41 |
| Support Level | $76.41 | N/A |
| Resistance Level | N/A | $115.56 |
| Average True Range (ATR) | 3.76 | 2.16 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 94.20 | 40.05 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.